Tokyo, Nov. 19 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059813) titled 'Efficacy and Safety of Escalating Once-weekly Semaglutide from 0.5 mg to 1.0 mg in Type 2 Diabetes:A Retrospective Observational Study' on Nov. 18.
Study Type:
Observational
Primary Sponsor:
Institute - Toho University Omori Medical Center
Condition:
Condition - Type 2 diabetes mellitus
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate metabolic parameters and the incidence of adverse events before and after dose escalation in patients with diabetes whose dose of once-weekly semaglutide is increased from 0.5 mg to 1.0 mg, and thereby assess the efficacy and safety of this dose escalation.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
60 g for men or >30 g for women), diagnosis of dementia, pregnancy during the data collection period, hospitalization for one week or longer for glycemic management during the data collection period, end-stage renal disease requiring maintenance dialysis at baseline, initiation of once-weekly semaglutide at another institution, insufficient follow-up time to obtain 24-week data (defined as having initiated the 1.0 mg dose less than 18 weeks prior to March 10, 2025), clinically significant non-adherence as judged by the treating physician, and patients deemed unsuitable for participation by the attending physician.
Target Size - 50
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2025 Year 07 Month 14 Day
Date of IRB - 2025 Year 08 Month 14 Day
Anticipated trial start date - 2025 Year 08 Month 14 Day
Last follow-up date - 2028 Year 01 Month 21 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068395
Disclaimer: Curated by HT Syndication.
